Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH, Montalbán X, Barkhof F, Radü E-W, Metzig C, et al. Lancet Neurol. 2009 Nov; 8(11):987-97. Epub 2009 Sep 10. PMID: 19748319. Abstract CommentRecommendBookmarkWatch